Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1CNS 1

Conditions

Glioblastoma 2Uterine Cervical Neoplasms 1Uterine Cervical Dysplasia 1Stomatitis 1Stomach Neoplasms 1Solid Tumor Refractory to Standard Therapy 1Sarcoma 1Precancerous Conditions 1Pancreatic Neoplasms 1Ototoxicity 1Mycosis Fungoides 1Mucositis 1Mouth Neoplasms 1Meningioma 1Lymphoma, T-Cell, Cutaneous 1Lymphoma, Non-Hodgkin 1Lymphoma, B-Cell, Marginal Zone 1Leiomyoma 1Hodgkin Disease 1Hearing Loss 1Head and Neck Neoplasms 1Gliosarcoma 1Fatigue 1Dermatomyositis 1Breast Neoplasms 1Brain Neoplasms 1Anemia 1

Interventions

Temozolomide 48Radiotherapy 26Radiation 13Chemotherapy, Adjuvant 9O(6)-benzylguanine 8Irinotecan 8Carmustine 8Surgical Procedures, Operative 7Magnetic Resonance Spectroscopy 6Erlotinib Hydrochloride 6motexafin gadolinium 5Radiotherapy, Intensity-Modulated 5Imatinib Mesylate 5sargramostim 4Radiotherapy, Conformal 4Hydroxyurea 4Gene Expression Profiling 4lonafarnib 3Radiosurgery 3Immunohistochemistry 3Genetic Therapy 3Filgrastim 3Drug Therapy 32,2-dimethyl-N-(6-oxo-6,7-dihydro-5H-dibenzo(b,d)azepin-7-yl)-N'-(2,2,3,3,3-pentafluoropropyl)malonamide 3vandetanib 2tipifarnib 2temsirolimus 2cediranib 2aldesleukin 2Vorinostat 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Gliosarcoma × Sodium Chloride × Clear all
NCT04216329 2026-01-23

Selinexor (KPT-330) in Combination With Temozolomide and Radiation Therapy in Patients With Newly Diagnosed Glioblastoma

National Institutes of Health Clinical Center (CC)

Phase 1 Active not recruiting
11 enrolled 19 charts
CNSSarcoma

Glioblastoma, Gliosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡